BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 2019;8:E1060. [PMID: 31331016 DOI: 10.3390/jcm8071060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Gutiérrez Cardo AL, Vallejo Casas JA, García Garzón JR, Tirado Hospital JL, Medina López R, Freire Macías JM, Rodríguez Fernández A. (18)F-DCFPyL PET/CT guidelines. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2023:S2253-8089(23)00026-5. [PMID: 36878314 DOI: 10.1016/j.remnie.2023.02.009] [Reference Citation Analysis]
2 Gutiérrez Cardo A, Vallejo Casas J, García Garzón J, Tirado Hospital J, Medina López R, Freire Macías J, Rodríguez Fernández A. Guía del procedimiento de la PET/TC con 18F-DCFPyL. Revista Española de Medicina Nuclear e Imagen Molecular 2023. [DOI: 10.1016/j.remn.2023.01.010] [Reference Citation Analysis]
3 Refardt J, Hofland J, Wild D, Christ E. Molecular Imaging of Neuroendocrine Neoplasms. J Clin Endocrinol Metab 2022;107:e2662-70. [PMID: 35380158 DOI: 10.1210/clinem/dgac207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 von Eyben FE, Bauman G, Kapp DS, Virgolini I, Paganelli G. On the Way for Patients with Prostate Cancer to the Best Use of PSMA. Int J Mol Sci 2022;23:2478. [PMID: 35269620 DOI: 10.3390/ijms23052478] [Reference Citation Analysis]
5 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kaissis G, Braren R. Artificial Intelligence Will Improve Molecular Imaging, Therapy and Theranostics. Which Are the Biggest Advantages for Therapy? Artificial Intelligence/Machine Learning in Nuclear Medicine and Hybrid Imaging 2022. [DOI: 10.1007/978-3-031-00119-2_12] [Reference Citation Analysis]
7 Mehata AK, Viswanadh MK, Solomon VR, Muthu MS. Radionanotheranostics for breast cancer diagnosis and therapy: recent advances and future opportunities. Targeted Nanomedicine for Breast Cancer Therapy 2022. [DOI: 10.1016/b978-0-12-824476-0.00018-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kronbichler J, Gabriel M. Sarkoidose als Pitfall in der 68 Ga-DOTANOC(Ga-SSTR)-PET/CT bei Patientin mit metastasiertem neuroendokrinem Tumor des Zökums. J Klin Endokrinol Stoffw 2020;13:51-53. [DOI: 10.1007/s41969-020-00098-6] [Reference Citation Analysis]
10 Velikyan I. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals (Basel) 2020;13:E39. [PMID: 32151049 DOI: 10.3390/ph13030039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Kunter U. Harnwegsinfektionen. Nephrologe 2020;15:119-131. [DOI: 10.1007/s11560-020-00408-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lapa C. Exciting Opportunities in Nuclear Medicine Imaging and Therapy. J Clin Med 2019;8:E1944. [PMID: 31718092 DOI: 10.3390/jcm8111944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]